Search
Search the current U.S. Code within Title 21
Search by citation or keyword across the current edition within Title 21.
21 U.S.C. § 360bbb–4a
Priority review to encourage treatments for agents that present national security threats
Priority review to encourage treatments for agents that present national security threats
21 U.S.C. § 360bbb–0
Expanded access policy required for investigational drugs
Expanded access policy required for investigational drugs
21 U.S.C. § 360bbb–0a
Investigational drugs for use by eligible patients
Investigational drugs for use by eligible patients
21 U.S.C. § 360bbb–3
Authorization for medical products for use in emergencies
Authorization for medical products for use in emergencies
21 U.S.C. § 360bbb–4
Countermeasure development, review, and technical assistance
Countermeasure development, review, and technical assistance
21 U.S.C. § 360bbb–8
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
21 U.S.C. § 360bbb–8c
Patient participation in medical product discussion
Patient participation in medical product discussion
21 U.S.C. § 360bbb–8d
Notification, nondistribution, and recall of controlled substances
Notification, nondistribution, and recall of controlled substances
21 U.S.C. § 379dd–2
Activities of the Food and Drug Administration
Activities of the Food and Drug Administration
21 U.S.C. § 360bbb
Expanded access to unapproved therapies and diagnostics
Expanded access to unapproved therapies and diagnostics